VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
Titel:
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
Auteur:
Oaknin, A. Gladieff, L. Martinez-Garcia, J. Villacampa, G. Takekuma, M. De Giorgi, U.F.F. Lindemann, K. Woelber, L. Colombo, N. Duska, L.R. Leary, A. Godoy Ortiz, A. Nishio, S. Angelergues, A. Rubio Perez, M.J. FariƱas Madrid, L. Yamaguchi, S. Lorusso, D. D'Hondt, V. Randall, L.